Is it Time to Take Your Profits From Opiant Pharmaceuticals Inc. [OPNT] Stock?

In a recent bid Opiant Pharmaceuticals Inc. [OPNT] faced a contemporary bid of $8.47 yielding a -3.31% decline where 0.57 million shares have exchanged hands over the last week. OPNT amount got a boost by 3.04% or $0.25 versus $8.22 at the end of the prior session. This change led market cap to move at 36.93M, putting the price 24.78% below the 52-week high and -45.98% above the 52-week low. The company’s stock has a normal trading capacity of 0.57 million shares while the relative volume is 23.09.

On 14, December 2020, Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program. According to news published on Yahoo Finance, Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1 million.

In the past 52 weeks of trading, this stock has oscillated between a low of $6.79 and a peak of $15.68. Right now, according to Wall Street analyst the average 12-month amount target is $40.00. At the most recent market close, shares of Opiant Pharmaceuticals Inc. [NASDAQ:OPNT] were valued at $8.47.


Opiant Pharmaceuticals Inc. [NASDAQ:OPNT] most recently reported quarterly sales of 9.11 billion, which represented growth of -55.80%. This publicly-traded organization’s revenue is $1,929,514 per employee, while its income is $552,050 per employee. This company’s Gross Margin is currently 78.40%, its Operating Margin is -1.60%, its Pretax Margin is +28.17, and its Net Margin is +28.61. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 33.28, 45.22, 41.93 and 45.00 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 2.19 and the whole liability to whole assets at 1.92. It shows enduring liability to the whole principal at 0.72 and enduring liability to assets at 0.01 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 8.31 points at 1st support level, the second support level is making up to 8.15. But as of 1st resistance point, this stock is sitting at 8.61 and at 8.76 for 2nd resistance point.

Opiant Pharmaceuticals Inc. [OPNT] reported its earnings at $0.15 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.21/share signifying the difference of 0.36 and 171.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.05 calling estimates for -$0.24/share with the difference of 0.19 depicting the surprise of 79.20%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Opiant Pharmaceuticals Inc. [NASDAQ:OPNT] is 6.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.52. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.90 and it’s amount to book ratio is 1.75.

Insider Stories

The most recent insider trade was by Thomas Thomas T., Director, and it was the purchase of 500.0 shares on Sep 04. Thomas Thomas T., the Director, completed a purchase of 2500.0 shares on Sep 03.